# Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

> **NCT05595590** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Tislelizumab
- **RADIATION:** Pulse radiation

## Key facts

- **NCT ID:** NCT05595590
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-20
- **Primary completion:** 2024-10-19
- **Final completion:** 2026-10-19
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05595590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05595590, "Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05595590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*